Particulate Matter in Injectables: USP <788> and the Packaging Contribution

What counts as particulate matter in an injection?

Particulate matter in an injection is any mobile, undissolved particle other than a gas bubble that is unintentionally present in the solution. The pharmacopoeias split it by size, because the two size ranges need different detection methods and carry different clinical arguments.

• Visible particulates are those an inspector can see under defined lighting during a manual or automated inspection. In practice the detection threshold sits in the region of 100 to 200 µm, depending on the particle, the container and the inspection conditions.
• Sub-visible particulates are those below the visual threshold, counted instrumentally. The pharmacopoeial size gates are 10 µm and 25 µm.

Industry practice, reflected in FDA’s guidance on inspection of injectable products for visible particulates, also classifies particles by where they came from:

• Inherent: arising from the formulation itself, for example protein aggregates or a suspension’s own solids.
• Intrinsic: arising from the manufacturing process or the packaging system, for example stainless steel wear, silicone oil, glass fragments, elastomer fragments or fibres from a component.
• Extrinsic: foreign to both process and product, for example environmental fibres, hair or insect parts.

Vial closures, meaning the elastomeric stopper and the aluminium or aluminium-plastic seal crimped over it, are a potential intrinsic source. That is the category the pharmaceutical manufacturer will interrogate a packaging supplier about. The question comes back from every therapeutic area that fills into small-volume vials, from cytotoxic and oncology products to vaccines.

USP <788>: the sub-visible limits

USP General Chapter <788>, Particulate Matter in Injections, is the compendial test for sub-visible particulate matter in injectable products, and it is harmonised across the USP, Ph. Eur. and JP. It provides two methods and expresses a clear preference for the first.

• Method 1, light obscuration particle count. A liquid sample passes through a sensor where each particle blocks a beam; the size and count are derived from the signal. This is the default method.
• Method 2, microscopic particle count. The sample is filtered onto a membrane and particles are counted under a microscope. It is used where light obscuration cannot be applied, for example with products that are not clear, are viscous, or contain air bubbles that the sensor would misread.

The limits differ by method and by container volume:

NMT means “not more than”. The chapter also sets out how many units to pool, how to prepare the test environment so it does not contribute particles of its own, and how to handle a first-stage failure. Because USP-NF is revised on a continuous cycle, confirm the current text and limits in the current USP-NF edition before writing a specification against them.

Two related chapters sit alongside <788> for specific product classes. USP <787> addresses sub-visible particulate matter in therapeutic protein injections, where smaller sample volumes and protein aggregates change the practicalities, so it is the chapter that applies to most biologic vial presentations. USP <789> addresses particulate matter in ophthalmic solutions, with its own limits, which makes particulate control a defining constraint on ophthalmic closures.

USP <790> and the 100% inspection expectation

USP <790>, Visible Particulates in Injections, is the standard that makes every unit subject to inspection. It states the quality attribute in the negative: injectable products should be “essentially free from visible particulates”. That phrase is a defined term rather than a claim of absolute absence. It means the product complies when it has been through a validated inspection process, applied to 100% of the units in the lot, and the number of units found to contain visible particulates is within the acceptance criteria.

The chapter is deliberately short on method. The method sits in USP <1790>, Visual Inspection of Injections, an informational chapter covering inspection booth conditions, inspector qualification and requalification, manual versus semi-automated versus fully automated inspection, defect libraries, and the lifecycle management of the inspection programme. Read together, <790> sets the standard and <1790> explains how to reach it defensibly.

The practical consequence for a packaging supplier is straightforward. Any particle that a closure sheds, whether an aluminium sliver from a poorly formed shell, a polypropylene flake from a button, or a fibre picked up in packing, becomes a reject at the customer’s inspection station. Rejects cost the customer yield, and a pattern of them triggers a supplier investigation.

The European position: Ph. Eur. 2.9.19, 2.9.20 and Annex 1

The European Pharmacopoeia covers the same ground through general chapters 2.9.19 for sub-visible particulate contamination and 2.9.20 for visible particulate contamination, published by the EDQM. Chapter 2.9.19 is harmonised with USP <788>, so the two methods and the numerical limits align; 2.9.20 covers the visible inspection.

On top of the pharmacopoeial tests, EU GMP Annex 1 (2022 revision) frames particulate control as part of the Contamination Control Strategy for sterile manufacture. Annex 1 expects filled and sealed containers to be inspected, expects defective units to be classified and trended, and expects the CCS to reach back into the supply chain, including the qualification and handling of primary packaging components. It binds the drug manufacturer rather than the component supplier, but it is the reason a component supplier is asked for particulate data at all. A fuller treatment is on the EU GMP Annex 1 page.

Where vial closures fit

A closure cannot pass or fail USP <788>; the drug product does. What a closure can do is contribute particles, and that contribution is controlled at the component supplier and at the customer’s washing and handling steps. Three parts of a sealed vial are relevant.

The elastomeric stopper. Rubber closures shed particles from their surface and can fragment when a needle pierces them. The dedicated test is ISO 8871-3, Elastomeric parts for parenterals and for devices for pharmaceutical use, Part 3: Determination of released-particle count, which specifies how to rinse a closure and count the visible and sub-visible particles released. Notably, ISO 8871-3 does not itself set limits: the standard leaves them to be agreed between the closure manufacturer and the user. Fragmentation on needle penetration is a separate functional attribute, handled under USP <382>, with material qualification under USP <381> and, in Europe, Ph. Eur. 3.2.9.

The glass vial. Glass contributes through delamination flakes and through chipping at the neck if the capping station is misaligned. Aluminium seal crimping is one of the mechanical operations at which glass can be stressed, which is why crimping force and head alignment are treated as validated parameters.

The aluminium or aluminium-plastic seal. The seal contributes in two ways. It can carry surface particulate from forming, punching and handling into the aseptic area, so seals for aseptic filling are washed and supplied ready to use. It can also generate particles at the capping station if the shell is dimensionally inconsistent, out of round, or if burrs are left from the punching operation. Consistent dimensions and a clean cut edge are the mechanical answer; washing, cleanroom assembly and sealed bagging are the contamination answer. The general construction is described on the aluminium-plastic seal manufacturing process page.

Controlling the packaging contribution

The controls that matter are set at the component manufacturer, before the seal ever reaches the fill line. Four of them do most of the work.

• Washing. An automated wash and rinse cycle removes forming lubricant residue, metal fines and airborne fibres picked up during production. Rinse water quality and the drying step determine how much of the removed material stays removed.
• Cleanroom assembly and packing. Assembling and bagging in a classified environment stops recontamination between washing and the customer’s airlock. ISO Class 8 is the common grade for this operation.
• 100% automated inspection. High-speed camera inspection rejects seals with burrs, deformed shells, missing or misaligned discs, and visible surface contamination. Because it is applied to every unit rather than to a sample, it catches the intermittent defect that an AQL sample plan can miss.
• Ready-to-use supply. Washed, bagged and sterilized components, supplied double-bagged, let the customer bring seals into the aseptic core without an in-house wash step, which removes one of the more particulate-prone operations from their process.

The quality-system framing for all of this is ISO 15378, the GMP standard for primary packaging materials, which is what a pharmaceutical customer audits a seal supplier against.

How this works in practice at Autofits

Particulate control at Autofits is built into the production route rather than tested in at the end. Components are washed on a fully automated line, assembled in an ISO Class 8 cleanroom, and every seal passes 100% high-speed camera inspection before packing. Ready-to-Use seals are washed to control particulates, then sterilized by gamma irradiation or ethylene oxide and supplied double-bagged for aseptic areas; Ready-to-Sterilize and Regular forms are available where the customer sterilizes in house. Tyvek bagging is offered where the customer’s airlock procedure requires it.

Materials are specified with the same logic. The shell is AA8011 aluminium with an epoxy lacquer coating conforming to 21 CFR 175.300, and the flip button is polypropylene to FDA 21 CFR 177.1520. Release runs against an AQL plan of critical nil, major not more than 2.5% and minor not more than 4%, tailorable to the customer’s own specification, on top of the 100% camera inspection. Production sits under ISO 9001:2015, ISO 14001:2015 and ISO 15378:2017 with a Drug Master File, in a 75,000 sq ft facility in Nashik, India. The certification set is on the quality page, and the seal range itself is on the FlipTop Optima product page. The same material and inspection controls apply across the full seal and cap range.

Frequently asked questions

What is USP <788>?

USP General Chapter <788>, Particulate Matter in Injections, is the compendial test for sub-visible particulate matter in injectable products. It provides two methods, light obscuration particle count (Method 1) and microscopic particle count (Method 2), and sets limits at the 10 µm and 25 µm size gates. Light obscuration is the default; the microscopic method is used where the product cannot be measured reliably by light obscuration.

What are the USP <788> particulate limits?

By light obscuration, small-volume injections of 100 mL or less must contain not more than 6,000 particles of 10 µm and larger and not more than 600 particles of 25 µm and larger per container. Large-volume injections of more than 100 mL must contain not more than 25 particles per mL at 10 µm and larger and not more than 3 per mL at 25 µm and larger. The microscopic method has its own, lower numerical limits. Confirm the current values in the current USP-NF edition.

What is the difference between USP <788> and USP <790>?

USP <788> covers sub-visible particulates and is a laboratory test on a sample of units, counted instrumentally at the 10 µm and 25 µm gates. USP <790> covers visible particulates and is an inspection applied to 100% of the units in the lot, establishing that the product is essentially free from visible particulates. They are complementary: one measures what an inspector cannot see, the other governs what an inspector can.

Does a vial seal have to pass USP <788>?

No. USP <788> is a test on the finished injectable product, not on a packaging component. A seal or stopper cannot be certified to <788>. What a closure supplier can provide is evidence of the controls that limit its particulate contribution, such as washing, cleanroom assembly, 100% camera inspection and ready-to-use supply, plus released-particle data for elastomeric parts generated to ISO 8871-3.

How do aluminium seals contribute to particulate matter?

Two ways. They can carry surface particulate from forming, punching and handling into the filling area, which is why seals for aseptic filling are washed, bagged and often supplied sterilized. They can also generate particles at the capping station if the shell is out of round, dimensionally inconsistent, or left with burrs from punching, since the crimping tool then works the metal unevenly. Dimensional consistency and clean cut edges are the mechanical controls.

What does “essentially free from visible particulates” mean?

It is the defined compliance state in USP <790>. It does not mean zero particles under any conceivable examination. It means the lot has been through a validated inspection process applied to every unit, under defined lighting and viewing conditions, and the number of units found to contain visible particulates falls within the acceptance criteria. USP <1790> describes how to design, validate and maintain that inspection programme.

Which European standards correspond to USP <788>?

Ph. Eur. 2.9.19 covers sub-visible particulate contamination and is harmonised with USP <788>, so the methods and limits align. Ph. Eur. 2.9.20 covers visible particulate contamination. Above the pharmacopoeial tests, EU GMP Annex 1 (2022 revision) places particulate control inside the Contamination Control Strategy for sterile manufacture and drives the inspection and trending expectations.

Related reading

• EU GMP Annex 1: sterile medicinal products
• USP <382>: elastomeric component functional suitability
• BSE/TSE compliance for pharmaceutical packaging
• ISO 15378: GMP for primary packaging materials
• Extractables and leachables for vial closures
• Sterile vial sealing
• Autofits quality and certifications

Sources

• USP: USP-NF General Chapter <788>, Particulate Matter in Injections (https://www.usp.org/)
• USP: USP-NF General Chapter <790>, Visible Particulates in Injections, and <1790>, Visual Inspection of Injections (https://www.usp.org/)
• EDQM: European Pharmacopoeia general chapters 2.9.19 and 2.9.20 (https://www.edqm.eu/en/european-pharmacopoeia)
• European Commission: EudraLex Volume 4, Annex 1, Manufacture of Sterile Medicinal Products, 2022 revision (https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en)
• FDA: Inspection of Injectable Products for Visible Particulates, Guidance for Industry (https://www.fda.gov/media/154868/download)
• ISO: ISO 8871-3:2003, Elastomeric parts for parenterals and for devices for pharmaceutical use, Part 3: Determination of released-particle count (https://www.iso.org/standard/33771.html)
• ISO: ISO 15378:2017, Primary packaging materials for medicinal products, GMP requirements (https://www.iso.org/standard/70729.html)

*Last updated: 2026-07-31. This article is general technical information, not regulatory or compliance advice; confirm current pharmacopoeial editions, chapter numbering and limits with USP, the EDQM and the issuing bodies before applying them to a specification.*